Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Kawaguchi-city, Japan Clinical Trials

A listing of Kawaguchi-city, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (22) clinical trials

Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer

Up-regulated ling cancer 10 (URLC10), TTK protein kinase (TTK) and K homology domain containing protein over expressed in cancer (KOC1) were identified as new targets of tumor associated antigens using cDNA microarray technologies combined with the expression profiles of normal and cancer tissues. Furthermore, anti-angiogenic therapy is now considered to ...

Phase

3.4 miles

Learn More »

A Study of OBP-301 With Radiation Therapy in Patients With Esophageal Cancer

After screening, patients will undergo a combination therapy of OBP-301 with radiation therapy for 6 weeks. At Day 1, Day 18 and Day 32, OBP-301 is directly injected to the location of the lesion. From Day 4, patients receive radiation therapy. Patients will be automatically entered follow-up period for 12 ...

Phase

3.83 miles

Learn More »

Dose-escalation Trial of the Safety Pharmacokinetics and Pharmacodynamics of Iron Isomaltoside (Monofer )

IDA is highly prevalent in subjects with cancer and gastrointestinal diseases such as inflammatory bowel diseases, menstruating or pregnant women, and subjects who have undergone bariatric procedure. IDA can have a substantial medical and quality of life (QoL) burden on the subjects, and treatment of these subjects includes controlling the ...

Phase

5.01 miles

Learn More »

A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine

The purpose of the study is the measure the levels of lasmiditan in the body of children aged 6 to 17 with migraine. The study also will also examine the safety and tolerability of lasmiditan in children aged 6 to 17 with migraine. The study will last about 6 weeks, ...

Phase

7.49 miles

Learn More »

A Study to Evaluate Safety Tolerability Pharmacokinetics and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease

The primary objective of this study is to evaluate the safety and tolerability of a range of single and 13 repeated doses of BIIB054, administered as intravenous (IV) infusion, in Japanese participants with Parkinson's disease (PD). The secondary objectives are to evaluate the immunogenicity, and serum pharmacokinetics (PK) profile of ...

Phase

7.59 miles

Learn More »

A Study Evaluating Safety and Tolerability and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Asian Adult Participants With Myeloproliferative Neoplasm

There are 2 parts to this study for which the primary objectives are to evaluate safety and tolerability, including dose-limiting toxicities (DLTs), and pharmacokinetics of navitoclax when administered alone (Part 1) or when administered in combination with ruxolitinib (Part 2). In Part 2, participants must have been receiving a stable ...

Phase

7.59 miles

Learn More »

Study of MK-7684 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001)

This is a safety, efficacy, and pharmacokinetics study of MK-7684 as monotherapy and in combination with pembrolizumab (MK-3475) or pembrolizumab plus pemetrexed and carboplatin in adults with metastatic solid tumors for which there is no available therapy that is expected to convey clinical benefit. Part A of this study is ...

Phase

7.87 miles

Learn More »

Study of MK-4280 as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy AND MK-4280A as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)

This is a safety and pharmacokinetics study of MK-4280 as monotherapy and in combination with pembrolizumab (MK-3475) AND MK-4280A as monotherapy in adults with metastatic solid tumors for which there is no available therapy which may convey clinical benefit. Part A of this study is a dose escalation design in ...

Phase

7.87 miles

Learn More »

Safety Pharmacokinetics (PK) and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001)

After screening, participants are assigned to either the Dose Escalation Phase or Dose Confirmation Phase. The Dose Escalation Phase consists of 3 cohorts and will evaluate available PK and safety data from the first 6 participants of each cohort, including dose limiting toxicities (DLTs). The purpose of the Dose Confirmation ...

Phase

7.88 miles

Learn More »

A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies

This is an open-label, multi-center, Phase 1 study of PF-04449913 in Japanese patients. PF-04449913 will be administered orally as a single agent in patients with select advanced hematologic malignancies, or in combination with LDAC [Low-Dose Ara-C] or cytarabine and daunorubicin in previously untreated patients with AML [Acute Myeloid Leukemia] or ...

Phase

8.22 miles

Learn More »